Breaking Finance News

Cara Therapeutics Inc (NASDAQ:CARA) stock price target upped to $21.73, released a research note earlier today by Vetr Inc.

Having a price of $19.50, Cara Therapeutics Inc (NASDAQ:CARA) traded -3.15% lower on the day. The last stock close price is up -18.32% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time. The company has recorded a 50-day moving average of $13.80 and a two hundred day average of $16.20. Volume of trade was down over the average, with 749,500 shares of CARA changing hands under the typical 2,588,690

Cara Therapeutics Inc (NASDAQ:CARA) had its stock price target increased to $21.73 by Vetr Inc. in an issued report issued 6/21/2017. The upped price target implies a potential upside of 0.11% based on the company's previous stock price close.

See Chart Below

Cara Therapeutics Inc (NASDAQ:CARA)

Cara Therapeutics Inc has a 52 week low of $5.85 and a one year high of $28.50 CARA’s market capitalization is presently $0.

General Company Details For Cara Therapeutics Inc (NASDAQ:CARA)

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.